Dionese Michele, Basso Umberto, Pierantoni Francesco, Lai Eleonora, Cavasin Nicolò, Erbetta Elisa, Jubran Salim, Bonomi Giorgio, Bimbatti Davide, Maruzzo Marco
Oncology Unit 1, Istituto Oncologico Veneto, IOV - IRCCS, Padova, 35128, Italy.
Oncology Unit 3, Istituto Oncologico Veneto, IOV - IRCCS, Padova, 35128, Italy.
Future Sci OA. 2023 Jun 24;9(7):FSO878. doi: 10.2144/fsoa-2023-0049. eCollection 2023 Aug.
Inflammation indexes had been associated with overall survival (OS) and immune-related adverse events (irAEs) in patients treated with immune checkpoint inhibitors (ICIs).
MATERIALS & METHODS: in 72 patients treated with ICIs for metastatic urothelial carcinoma (mUC) we evaluate differences in OS, response rate and toxicities, according to baseline inflammation indexes values.
neutrophil-to-lymphocite ratio (NLR) <3 was associated to longer progression-free survival (PFS; 4.9 vs 3.1 months) and OS (15.7 vs 7.6 months); monocyte-to-lymphocite ratio (MLR) <0.4 was associated to longer PFS (4.6 vs 2.8 months). Overall response rate (ORR), disease control rate (DCR) were higher in these patients. Patients with an irAE had longer PFS and OS.
baseline inflammatory indexes are prognostic for mUC patients treated with ICIs.
炎症指标与接受免疫检查点抑制剂（ICI）治疗的患者的总生存期（OS）和免疫相关不良事件（irAE）相关。
在72例接受ICI治疗转移性尿路上皮癌（mUC）的患者中，我们根据基线炎症指标值评估了OS、缓解率和毒性的差异。
中性粒细胞与淋巴细胞比值（NLR）<3与更长的无进展生存期（PFS；4.9个月对3.1个月）和OS（15.7个月对7.6个月）相关；单核细胞与淋巴细胞比值（MLR）<0.4与更长的PFS（4.6个月对2.8个月）相关。这些患者的总缓解率（ORR）、疾病控制率（DCR）更高。发生irAE的患者有更长的PFS和OS。
基线炎症指标对接受ICI治疗的mUC患者具有预后意义。
